{"product_id":"phat-marketing-mix","title":"(PHAT) Phathom Pharmaceuticals, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Phathom Pharmaceuticals, Inc. 4P's Marketing Mix Analysis explains the company’s product offering, its clinical uses, pricing approach, distribution channels, and promotional tactics in a concise, structured view; this page includes a real preview\/sample of the analysis so you can judge style and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVOQUEZNA tablets 10 mg and 20 mg\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVOQUEZNA tablets 10 mg and 20 mg are Phathom Pharmaceuticals, Inc.’s core U.S. branded product, with vonoprazan as an oral potassium-competitive acid blocker (P-CAB) built to suppress gastric acid. In 2025, Phathom kept VOQUEZNA as its main commercial driver in acid-related gastrointestinal disease. The 10 mg and 20 mg strengths support different treatment needs, which helps widen use across the category.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVOQUEZNA TRIPLE PAK\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVOQUEZNA TRIPLE PAK is Phathom Pharmaceuticals, Inc.’s 14-day H. pylori kit, combining vonoprazan, amoxicillin, and clarithromycin in a 3-drug regimen. It is used as combination therapy to help eradicate Helicobacter pylori infection, with the pack format built for short-course prescription use. The 14-day design supports simpler dosing and a clear treatment window for patients and prescribers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVOQUEZNA DUAL PAK\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVOQUEZNA DUAL PAK is a 14-day H. pylori regimen that combines vonoprazan and amoxicillin, giving Phathom Pharmaceuticals, Inc. a non-clarithromycin option for patients who do not need triple therapy. It is packaged for regimen-based dispensing, which supports simpler pharmacy handling and better adherence in a 2-antibiotic treatment course.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGI acid suppression platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePhathom Pharmaceuticals, Inc. centers its GI acid suppression platform on vonoprazan, a potassium-competitive acid blocker that delivers faster and more sustained acid control than traditional PPIs. The portfolio is highly concentrated: Voquezna is the core commercial franchise, so product risk and upside both hinge on one molecule and one GI category.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVonoprazan is the key differentiator.\u003c\/li\u003e\n\u003cli\u003eDesigned for stronger, longer acid control.\u003c\/li\u003e\n\u003cli\u003ePhathom is a single-franchise GI company.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercial rights in 3 regions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePhathom Pharmaceuticals, Inc. controls commercial rights to vonoprazan in the United States, Europe, and Canada, giving it one core asset with room to scale across three major markets. In 2025, Phathom reported full-year net product revenue of about $200 million, showing the asset is already driving cash generation. That setup supports today’s U.S. rollout and future regional expansion without changing the base product.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne asset, three-region rights\u003c\/li\u003e\n\u003cli\u003eU.S. revenue engine already active\u003c\/li\u003e\n\u003cli\u003eEurope and Canada add expansion upside\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVOQUEZNA Drives Phathom’s $200M Sales Engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePhathom Pharmaceuticals, Inc. Product is built around VOQUEZNA, a vonoprazan-based P-CAB in 10 mg and 20 mg tablets, plus VOQUEZNA TRIPLE PAK and DUAL PAK for 14-day H. pylori treatment. In 2025, net product revenue was about $200 million, showing the franchise is already the company’s main sales engine. One molecule drives the whole lineup, so Product strength and risk both stay tightly linked.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product revenue\u003c\/td\u003e\n\u003ctd\u003e~$200 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore molecule\u003c\/td\u003e\n\u003ctd\u003eVonoprazan\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain franchise\u003c\/td\u003e\n\u003ctd\u003eVOQUEZNA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a concise, company-specific 4P’s analysis of Phathom Pharmaceuticals, Inc.’s product, pricing, distribution, and promotion strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear snapshot of Phathom’s 4Ps, helping teams quickly spot pain points and align on marketing actions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources that link each key Phathom Pharmaceuticals claim to traceable industry reports, trials, and datasets to speed due diligence and boost confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. prescription market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhathom Pharmaceuticals, Inc.’s U.S. prescription market is the main channel for VOQUEZNA, which is dispensed only through healthcare providers and pharmacies, not retail shelves. In 2025, the company reported VOQUEZNA net product revenue of $147.0 million, showing this prescription channel is the core demand driver. Physicians shape access and pharmacies control fulfillment, so prescribing and reimbursement matter most.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail pharmacy dispensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVOQUEZNA is filled through retail pharmacies after a clinician writes the order, so it fits normal outpatient workflows and keeps access simple for patients. This channel supports use by both insured and cash-pay patients, which matters for a drug launched in 2023 across U.S. pharmacy networks. It also helps Phathom Pharmaceuticals, Inc. avoid specialty-pharmacy friction and keeps the product visible at the point of dispense.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty access and payer channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhathom Pharmaceuticals, Inc. uses specialty pharmacy and payer channels to move VOQUEZNA to patients, so prior authorization and formulary status can decide how fast the drug is filled. For newer branded GI drugs, this gatekeeping is normal, and one missed payer step can delay therapy. Access work is as important as promotion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGastroenterology and primary care offices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePhathom Pharmaceuticals, Inc. relies on gastroenterology and primary care offices because that is where GERD and H. pylori patients are diagnosed, treated, and refilled. The \"place\" is not a store shelf; it is the prescribing site. \u003c\/p\u003e\n\u003cp\u003eGastroenterologists drive specialist demand, while primary care clinicians handle first visits and follow-up, so both offices shape access and persistence. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDiagnosis starts in clinic\u003c\/li\u003e\n\u003cli\u003ePrescribing happens in-office\u003c\/li\u003e\n\u003cli\u003eFollow-up drives refills\u003c\/li\u003e\n\u003cli\u003eOffice access shapes uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFlorham Park, New Jersey headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePhathom Pharmaceuticals, Inc. is headquartered in Florham Park, New Jersey, and the site supports commercial, medical, and corporate functions. That gives the Company a U.S.-based base for launch work, clinician outreach, and day-to-day management.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFlorham Park, New Jersey base\u003c\/li\u003e\n\u003cli\u003eSupports commercial and medical teams\u003c\/li\u003e\n\u003cli\u003eAnchors U.S. market execution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor the 4P analysis, this location strengthens Place by keeping key decision-makers close to U.S. customers and partners. It also helps Phathom Pharmaceuticals manage operations from one domestic hub.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVOQUEZNA’s U.S. Rx pharmacy channel drives $147.0M in 2025 revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePhathom Pharmaceuticals, Inc.’s Place strategy is U.S. prescription access: VOQUEZNA is written in clinics and filled through retail and specialty pharmacies, not sold on shelves. In 2025, net product revenue reached $147.0 million, showing this channel is the main path to patients. Prior authorization and formulary status still shape speed and volume.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace factor\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVOQUEZNA channel\u003c\/td\u003e\n\u003ctd\u003eU.S. Rx pharmacies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product revenue\u003c\/td\u003e\n\u003ctd\u003e$147.0 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain gatekeepers\u003c\/td\u003e\n\u003ctd\u003ePhysicians, payers, pharmacies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003ePhathom Pharmaceuticals, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Phathom Pharmaceuticals 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises; it covers Product, Price, Place, and Promotion with actionable insights and data-driven recommendations tailored to Phathom.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHCP sales force promotion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhathom Pharmaceuticals, Inc. promotes VOQUEZNA mainly through a field-based sales force that calls on healthcare professionals, which is the standard model for prescription GI brands. This channel helps explain clinical data, the 10 mg and 20 mg dosing options, and patient fit; in 2025, the message stayed centered on HCP education rather than direct-to-consumer reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGI specialist education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhathom Pharmaceuticals, Inc. focuses promotion on GI specialists treating GERD and H. pylori, covering 2 key use cases for vonoprazan. Educational outreach explains its mechanism as a potassium-competitive acid blocker and why it differs from PPIs. The message is clinical: better acid control, clear patient selection, and use in specialist-led care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific and medical congress activity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScientific meetings matter for Phathom Pharmaceuticals, Inc. because Voquezna is still in the early adoption phase, so every poster, symposium, and publication helps turn trial data into prescriber trust. In 2025, this channel stayed key for a biopharma company with only one commercial brand, since GI congresses like ACG and DDW shape specialist prescribing. Strong congress activity can speed uptake without heavy direct sales spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatient awareness and digital outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePhathom Pharmaceuticals, Inc. can use branded and disease-awareness ads to reach the about 20% of U.S. adults with weekly GERD symptoms and the roughly 35% of people worldwide with H. pylori infection. Digital channels fit GI care because they can explain symptoms, testing, and treatment, while keeping the Company Name top of mind. That can drive both physician demand and patient requests.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets reflux and H. pylori patients\u003c\/li\u003e\n\u003cli\u003eUses education to build recall\u003c\/li\u003e\n\u003cli\u003eSupports doctor and patient pull-through\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCopay and support programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePhathom Pharmaceuticals, Inc. uses copay and support programs to cut pharmacy friction for VOQUEZNA, a branded prescription drug. These offers can lower out-of-pocket cost at fill time, which helps turn a prescription into an actual dispense and can improve persistence after the first fill.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduces pharmacy counter friction\u003c\/li\u003e\n\u003cli\u003eSupports first-fill conversion\u003c\/li\u003e\n\u003cli\u003eHelps persistence on branded therapy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVOQUEZNA’s 2025 Growth Was Powered by HCPs, Congresses, and Copay Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Phathom Pharmaceuticals, Inc. kept VOQUEZNA promotion mostly HCP-led, with GI specialists, congresses, and disease education doing the heavy lift. The message stayed on vonoprazan’s faster acid control and fit for GERD and H. pylori, while copay support reduced fill friction and helped convert scripts into paid claims.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePromotion lever\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCP sales force\u003c\/td\u003e\n\u003ctd\u003eCore channel\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGI congresses\u003c\/td\u003e\n\u003ctd\u003eTrust builder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCopay support\u003c\/td\u003e\n\u003ctd\u003eLifted fills\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBranded prescription pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVOQUEZNA is a branded prescription acid-suppression therapy, so Phathom Pharmaceuticals, Inc. can price it above OTC PPIs instead of competing on commodity pricing. Its market value comes from prescription-only access and clinical differentiation, not generic substitution. In 2025, Phathom kept VOQUEZNA as its core revenue driver, with premium pricing supporting gross-to-net discipline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePack-based regimen pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhathom Pharmaceuticals, Inc. uses pack-based pricing for Voquezna, with 14-day Triple Pak and Dual Pak regimens tied to H. pylori use, so the bill matches the exact treatment path.\u003c\/p\u003e\n\u003cp\u003eThe product comes in 10 mg and 20 mg tablet strengths, and each pack covers the full 14-day course, which keeps pricing linked to the prescribed indication instead of a flat bottle price.\u003c\/p\u003e\n\u003cp\u003eThis model fits H. pylori drugs, where regimen length and drug mix drive cost, and it helps support clearer reimbursement for each separate pack.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance coverage matters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsurance coverage drives Phathom Pharmaceuticals, Inc. pricing because final patient cost can swing from a low copay to full cash pay based on formulary tier, deductibles, and coinsurance. Prior authorization and step edits can delay fills and raise out-of-pocket costs, so reimbursement access is part of the price strategy. For a branded GI drug like Voquezna, payer rules can matter as much as the list price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCopay assistance lowers out-of-pocket cost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePhathom Pharmaceuticals, Inc. can use copay cards and patient-support programs to cut the cash hit from its branded GI drugs, which often carry four-figure monthly list prices. In this market, even a small reduction in out-of-pocket cost can lift first-fill and refill rates fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLowers sticker shock\u003c\/li\u003e\n\u003cli\u003eSupports insured patients\u003c\/li\u003e\n\u003cli\u003eHelps drive adherence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePayer contracting and rebates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePhathom Pharmaceuticals, Inc. depends on payer contracts and pharmacy-benefit managers to shape net realized price for VOQUEZNA. Rebates, formulary coverage, and specialty-channel routing can materially reduce revenue per prescription, so this is one of the company’s main pricing levers. In specialty biotech, gross-to-net discounts often run in the 20%-50% range.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNet price depends on rebates\u003c\/li\u003e\n\u003cli\u003eCoverage terms drive volume\u003c\/li\u003e\n\u003cli\u003eChannel mix changes revenue\u003c\/li\u003e\n\u003cli\u003eKey lever for specialty pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVOQUEZNA’s Premium Pricing Hinges on Payer Access and Pack Design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVOQUEZNA is priced as a premium Rx therapy, not a commodity PPI, so Phathom Pharmaceuticals, Inc. can hold list price above OTC options. Its 14-day Triple Pak and Dual Pak, plus 10 mg and 20 mg strengths, tie price to treatment length. Net price still depends on payer access, rebates, and copay help; gross-to-net in specialty biotech often runs 20%-50%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePrice lever\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePack-based pricing\u003c\/td\u003e\n\u003ctd\u003e14-day Triple Pak\/Dual Pak\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrengths\u003c\/td\u003e\n\u003ctd\u003e10 mg and 20 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet haircut\u003c\/td\u003e\n\u003ctd\u003e20%-50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234879349001,"sku":"phat-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/phat-marketing-mix.webp?v=1785728563","url":"https:\/\/dcfanalyst.com\/products\/phat-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}